We have investigated the biochemical mechanism of tumor necrosis factor (TNF)-K-induced release of plasminogen activator inhibitor-1 (PAI-1) from human umbilical vein endothelial cells (HUVEC). Treatment of HUVEC with TNF-K for 3 h resulted in a 2.8-fold increase in the PAI-1 release compared with control. The increase in PAI-1 release was accompanied by a 133% increase in the intracellular acidic sphingomyelinase (SMase) activity. High-performance liquid chromatographic (HPLC) analysis revealed that the intracellular ceramide levels increased to 126% of the control (P 6 0.05), but the contents of membranous ceramide remained unaltered. We have previously shown that a cell-permeable ceramide analog, Nacetylsphingosine (C 2 -ceramide) enhances the PAI-1 release from HUVEC. Here, N-acetylsphinganine (C 2 -dihydroceramide) was found to specifically suppress both C 2 -ceramide-and TNF-K-induced increase in PAI-1 release from HUVEC without affecting the control PAI-1 release. Treatment of HUVEC with staphylococcal SMase that may mimic the activation of the membranous neutral SMase also increased the PAI-1 release. The increase in PAI-1 release by this mechanism was suppressed by a cyclooxygenase inhibitor, aspirin, whereas the inhibitor did not affect TNF-K-induced increase in PAI-1 release. Taken together, these findings suggest that TNF-K prominently utilizes the lysosomal acidic SMase-ceramide signaling pathway in the induction of PAI-1 release from HUVEC. ß 1998 Elsevier Science B.V. All rights reserved.
Introduction
Plasminogen activator inhibitor-1 (PAI-1) plays an important role in the regulation of ¢brinolysis by inactivating rapidly both tissue-type and urokinasetype plasminogen activators [1, 2] . Suppression of ¢-brinolysis through the elevated levels of plasma PAI-1 has been frequently found in coronary artery dis-ease patients [3, 4] . The PAI-1 production by vascular endothelial cells is increased by a number of cellular stimuli including endotoxin [5] , thrombin [6] , lipoprotein(a) [7] , interleukin-1 [8] and tumor necrosis factor-K (TNF-K) [9, 10] . The concentration of plasma PAI-1 is dramatically increased during endotoxemia. Endotoxin can induce the release of TNF-K from vascular endothelium. TNF-K thereafter induces tissue factor activity in the endothelial cells [11] which leads to the generation of a PAI-1 stimulator, thrombin [6] , suggesting its key roles in the PAI-1-related thromboembolic diseases.
TNF-K is known to interact with two distinct cell surface receptors of 55 and 75 kDa, respectively, that transmit signals down to the cytoplasm and nucleus to initiate profound alterations of the transcriptional programs [12] . Recently, several reports implicated the lipid messenger ceramide in various important pathways of TNF-K action [13] . In U937 cells, TNF-K, through binding to the 55 kDa receptor, rapidly activates two distinct types of sphingomyelinases (SMases), a cell membrane-bound neutral SMase and a lysosomal acidic SMase. Ceramide generated by the neutral SMase directs the activation of proline-directed serine/threonine protein kinases and phospholipase A 2 . In contrast, the acidic SMase triggers the activation of NF-UB through the generated ceramide [14] .
We have previously shown that cultured human umbilical vein endothelial cells (HUVEC) increase the release of PAI-1 by being treated with staphylococcal SMase or cell-permeable ceramide analogs, such as N-acetylsphingosine (C 2 -ceramide) [15] . These results suggested a possible involvement of ceramide in the induction of PAI-1 release. The present study was undertaken to investigate whether TNF-K utilizes ceramide as a signaling molecule for the induction of PAI-1 release. The results demonstrate that ceramide, generated in endosomal/lysosomal compartments, but not in cell membranes, may play a prominent role in the TNF-K signaling.
Materials and methods

Materials
The following materials were commercially obtained: C 2 -ceramide, Staphylococcus aureus SMase, 2-hexadecanoylamino-4-nitrophenylphosphorylcholine (HNP), ribonuclease A (RNase A) and proteinase K from Sigma; recombinant human TNF-K (1.0U10 8 units/mg protein) from Boehringer Mannheim; C 2 -dihydroceramide from Biomol, Plymouth Meeting, PA; aspirin from Wako, Osaka, Japan; (+)-6-methoxy-K-methyl-2 naphthaleneacetic acid (NAP), N,NP-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) from Aldrich; aspirin from Wako, Osaka, Japan; 500 bp DNA ladder from Takara Shuzo, Shiga, Japan.
HUVEC culture
HUVEC (passage 2) and the culture medium EGM-MV were purchased from Sanko Junyaku, Tokyo, Japan. The cells (6U10 5 cells) were plated into a 175-cm 2 tissue culture £ask (Falcon) and grown to near con£uency in EGM-MV (modi¢ed MCDB 131 medium that was supplemented with 5% fetal bovine serum, 10 ng/ml epidermal growth factor, 1 Wg/ml hydrocortisone, 50 Wg/ml gentamycin, 50 ng/ml amphotericin B and 12 Wg/ml bovine brain extract) at 37³C in a humidi¢ed 5% CO 2 atmosphere. The medium was renewed every 2 days. Subcultures were obtained by treating the HUVEC cultures with 0.25% trypsin/0.01% EDTA (JRH, Lenexa, KS) at 37³C for 5 min. All experiments were performed with HUVEC in the 6th to 8th passages.
Treatment of HUVEC with various agents
The passaged cells were seeded at a density of 2.5U10 3 cells/cm 2 onto collagen-coated 6-well tissue culture plate in EGM-MV and allowed to reach con£uency. After removal of the conditioned media, the HUVEC monolayers were rinsed twice with 2 ml of Dulbecco's modi¢ed Eagle's medium (DMEM). The HUVEC monolayers were then treated at 37³C for 30 min with 3 ml of DMEM. After removal of DMEM, incubation followed at 37³C in 3 ml of DMEM supplemented with or without the indicated agent(s). Ceramide analogs were dissolved in ethanol, and the other agents were in phosphate-bu¡ered saline (PBS). During treatment with these agents, control HUVEC were treated with an identical volume of the vehicle. At de¢nite times, 100 Wl of the con-ditioned media was withdrawn and subjected to the assay of PAI-1 antigen.
Assay of PAI-1 antigen
Antigen levels of PAI-1 in the conditioned media were determined with an ELISA kit, Imulyse PAI-1 (Biopool, Umea «, Sweden), according to the manufacturer's instructions.
Determination of cellular ceramide
Con£uent cultures of HUVEC in 175-cm 2 tissue culture £asks were rinsed with DMEM and incubated at 37³C for 30 min in 20 ml of DMEM. After removal of the conditioned media, incubation followed at 37³C for 3 h in 20 ml of DMEM supplemented with or without TNF-K (200 U/ml). Each cell culture was detached by treatment with 10 ml of 0.05% trypsin/0.53 mM EDTA (Gibco-BRL), and pelleted by centrifugation. The pellet was washed three times with 10 ml of cold PBS, and centrifuged again. The washed cells (5U10 6 ) were resuspended in 220 Wl of cold PBS/0.25 M sucrose, transferred into a microtube, and disrupted by sonication. After the cell lysate was centrifuged at 800Ug for 10 min, the supernatant (cytosol plus organelle fraction) was withdrawn. The pellet was washed three times with 1 ml of cold PBS, centrifuged, and suspended in 220 Wl of PBS (cell membrane fraction). The following lipid extraction and ceramide determination in each fraction were carried out according to the method of Previati et al. [16] . Brie£y, each fraction (200 Wl) was mixed with 4 ml of chloroform/methanol (2:1) and extracted for 30 min. After the addition of 1 ml of water, the sample was vortexed and centrifuged. The lower phase was collected and evaporated to dryness under a nitrogen stream. The residue was dissolved in 100 Wl of chloroform, and the solution was reacted at 320³C for 3 h with 100 mM NAP, 100 mM DCC and 100 mM DMAP (10 Wl each). After evaporation of the solvent under a nitrogen stream, the residue was suspended in 15 Wl of chloroform. The suspension was mixed with 2 ml of hexane and centrifuged. The supernatant was vigorously mixed with 5 ml of methanol/water (4:1) and centrifuged. A part (1 ml) of the upper phase was collected and ¢ltered through a 0.45-Wm membrane ¢lter. The HPLC system consisted of a Model 600 solvent delivery system (Waters), a Model 474 £uo-rescence detector (Waters) and a Model 805 data station (Waters). A 20-Wl portion of the ¢ltrate was injected into an Econosphere CN 5U column (4.6U250 mm, Alltech). The derivatized ceramide was separated from by-products with 3% 2-propanol in n-hexane as the mobile phase. The £ow rate was 2.0 ml/min, and the e¥uent was monitored £uoro-metrically at the excitation wavelength of 230 nm and emission wavelength of 352 nm.
Determination of acidic SMase activity
The acidic SMase activity in HUVEC was determined photometrically with HNP as a substrate [17] . The fractions of cell membrane and cytosol plus organelles derived from TNF-K-treated or untreated HUVEC were used as enzyme sources. Brie£y, the assay mixture contained the following components in a total volume of 100 Wl: 15 mM HNP, 250 mM sodium acetate bu¡er (pH 5.6) containing 0.05% Tween 80 and 50 Wl enzyme preparation. The enzyme reaction was carried out at 37³C and terminated with 400 Wl of 100 mM glycine bu¡er (pH 10.5) plus 700 Wl ethanol. The tube was vortexed and centrifuged at 2000Ug for 10 min. The absorbance of the supernatant solution was determined at 410 nm.
Assay of cell death and cell lysis
The lysis of HUVEC was measured with a commercial cytotoxicity detection kit (Boehringer Mannheim). This assay method is based on the measurement of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the supernatant.
Analysis of DNA fragmentation by agarose gel electrophoresis
HUVEC (1U10 6 cells) were harvested and pelleted by centrifugation at 400Ug for 5 min. The pellet was washed with cold PBS and resuspended in 20 Wl of a lysis bu¡er, 50 mM Tris-HCl bu¡er (pH 7.8)/10 mM EDTA/0.5% sodium N-lauroylsarcosinate. To the suspension was added 1 Wl of RNase A (10 mg/ml in the lysis bu¡er) and incubation followed at 50³C for 30 min. The reaction mixture was mixed with 1 Wl of proteinase K (10 mg/ml in the lysis bu¡er) and incubated again at 50³C for 60 min. After centrifugation, the nuclei sample was electrophoresed at 100 V on 1.5% agarose gel containing 0.5 Wg/ml ethidium bromide. DNA was visualized under UV light and photographed.
Statistical analysis of data
All values are expressed as the means þ S.D., and the signi¢cant levels between groups were assessed by Student's t test.
Results
TNF-K-induced increase in PAI-1 release from
HUVEC is accompanied by an increase in intracellular ceramide content and acidic SMase activity
We ¢rst examined the e¡ect of TNF-K on PAI-1 release from HUVEC. TNF-K increased the PAI-1 release in a dose-dependent manner, and the maximal levels of PAI-1 (35.3 þ 1.00 ng/ml, a 2.8-fold increase compared with control) were observed at a 3-h incubation with 200 U/ml TNF-K. The leakage of LDH activity from the TNF-K-treated HUVEC was not di¡erent from the control level, suggesting that the cytokine-inducible cellular lysis can be negligible (data not shown). Next, to determine whether TNF-K could alter the cellular ceramide levels, con£uent cultures of HUVEC were treated for 3 h in DMEM supplemented with or without TNF-K (200 U/ml) and then fractionated into cell membranes and cytosol plus organelles, respectively (see Section 2). As shown in Fig. 1A , TNF-K increased the net content of ceramide in the cytosol plus organelle fraction to 126% of the control (639 þ 18. 3 ng vs. 803 þ 64.7 ng, P 6 0.05). However, this cytokine did not alter the membranous ceramide content, suggesting little or no involvement of the activation of membranous neutral SMase. On the other hand, there was a 33% increase (P 6 0.01) in the net activity of acidic SMase (HNP hydrolysis at pH 5.6) present in the cytosol plus organelles derived from TNF-K-treated HUVEC (Fig. 1B) . This result implies the possibility that TNF-K may prominently activate the acidic SMase located in endosomal/lysosomal compartments.
3.2. C 2 -dihydroceramide suppresses both C 2 -ceramideand TNF-K-induced increases in PAI-1 release from HUVEC Olivera et al. [18] previously demonstrated that Fig. 1 . E¡ect of TNF-K on the intracellular ceramide levels (A) and acidic SMase activity (B) in HUVEC. Cultured HUVEC were stimulated with TNF-K (200 U/ml) at 37³C for 3 h, and then the cells were harvested and fractionated as described in Section 2. Ceramide levels were determined by a HPLC method. SMase activity was determined with HNP as the substrate. Each bar represents the mean þ S.D. of triplicate experiments. *P 6 0.05; **P 6 0.01, compared to control.
staphylococcal SMase or cell-permeable ceramide analogs, such as C 2 -ceramide, stimulated the proliferation of Swiss 3T3 cells and suggested that ceramide was involved in the cellular proliferation induced by various growth factors. By using the same experimental techniques, we also suggested the involvement of ceramide in the induction of PAI-1 release from HUVEC [15] . Fig. 2A and B show the concentration-dependent e¡ects of C 2 -ceramide and SMase, respectively, on the release of PAI-1 from cultured HUVEC. By a 3-h incubation of HUVEC with 10 WM C 2 -ceramide, the PAI-1 antigen level rose from 22.3 þ 0.25 to 47.3 þ 1.57 ng/ml (a 2.1-fold increase). The treatment of HUVEC for 3 h with 0.2 U/ml SMase caused a nearly maximal e¡ect on the PAI-1 release, and the increased PAI-1 antigen levels were 3.1-fold the control level (16.2 þ 0.95 ng/ml). However, the leakage of LDH activity from the HUVEC, treated for 3 h with 10 WM C 2 -ceramide or 0.2 U/ml SMase, was similar to that of control (data not shown). We also examined the e¡ect of C 2 -ceramide on the internucleosomal DNA fragmentation in HUVEC to know whether the C 2 -ceramide-induced PAI-1 release was due to the results from its leakage followed by apoptosis. The cells were incubated for 3^24 h in DMEM supplemented with or without C 2 -ceramide. The genomic DNA of HUVEC was not a¡ected by a 3-h incubation with either 10 or 20 WM C 2 -ceramide, although at a 24-h incubation the DNA fragmentation was more clearly observed in C 2 -ceramide-treated HUVECs (data not shown). Therefore, these ¢ndings indicate that the increase in PAI-1 release at 3 h is not due to the results from cellular lysis or apoptosis in HUVEC by the agent, suggesting the primary role of C 2 -ceramide as a lipid messenger for the PAI-1 production. During the experiments that have examined the concentration-dependent e¡ects of C 2 -ceramide and SMase on the PAI-1 release (Fig. 2A,B) , we found that 20 WM C 2 -ceramide and SMase (0.2 U/ml) in combination could synergistically increase the PAI-1 release from 51.1 þ 1.64 to 72 þ 2.76 ng/ml (data not shown). This ¢nding suggested a possibility that ceramide generated by staphylococcal SMase at plasma membrane and C 2 -ceramide incorporated into the cells might utilize di¡erent signal transduction pathways. To determine this possibility, experiments were undertaken to examine the e¡ect of C 2 -dihydroceramide on the C 2 -ceramide-or SMase-induced PAI-1 release from HUVEC, since C 2 -dihydroceramide di¡ers from C 2 -ceramide only in that it lacks the 4,5 trans double bond and has no C 2 -ceramide-like activity. As shown in Fig. 3A , C 2 -dihydroceramide e¡ectively suppressed the C 2 -ceramideinduced increase in PAI-1 release to near the control levels (control, 15.8 þ 2.63 ng/ml vs. C 2 -ceramide plus C 2 -dihydroceramide, 21.1 þ 3.65 ng/ml). However, the PAI-1 release was not a¡ected by this compound alone (15.9 þ 1.13 ng/ml). C 2 -dihydroceramide had little or no e¡ect on the SMase-induced increase in PAI-1 release (SMase alone, 67.2 þ 9.13 ng/ml vs. SMase plus C 2 -dihydroceramide, 64.4 þ 14.8 ng/ml). We next examined the e¡ect of C 2 -dihydroceramide on TNF-K-induced increase in PAI-1 release (Fig.  3B) . C 2 -dihydroceramide at 6.5^25 WM signi¢cantly suppressed the TNF-K-induced PAI-1 release in a concentration-dependent manner (TNF-K alone, 31.3 þ 2.29 ng/ml vs. TNF-K plus 25 WM C 2 -dihydroceramide, 18.9 þ 1.78 ng/ml, P 6 0.05). Higher concentrations of C 2 -dihydroceramide (50 WM) did not cause a further increase in the suppressive e¡ect (data not shown). This ¢nding indicates that C 2 -dihydroceramide competes with the incorporated C 2 -ceramide for the induction of PAI-1 and additionally that it could also compete with the intracellular ceramide generated by acidic SMase after induction by TNF-K (Figs. 1B and 2A) .
To further con¢rm this possibility, we next attempted to use a cyclooxygenase inhibitor, aspirin, for the inhibition of TNF-K-induced PAI-1 release from HUVEC. Treatment of HUVEC with staphylococcal SMase that mimics the action of neutral SMase may hydrolyze the membrane SM to ceramide and phosphocholine. The membrane ceramide signal transduction pathway may direct the activation of proline-directed serine/threonine protein kinases and phospholipase A 2 [14] . The activation of phospholipase A 2 could generate prostaglandins via activation of cyclooxygenase. As shown in Fig. 4A , C 2 -ceramide-induced increase in PAI-1 release was not a¡ected by the clinically useful concentrations of aspirin (28.4 þ 3.59 ng/ml vs. 26.8 þ 2.06 ng/ml). However, the presence of 5 or 20 Wg/ml aspirin decreased SMase-induced PAI-1 release to the control levels (control, 16.0 þ 0.51 ng/ml vs. SMase plus 20 Wg/ml aspirin, 17.9 þ 0.72 ng/ml). Additionally, 5 or 20 Wg/ml aspirin had no e¡ect on the TNF-Kinduced PAI-1 release from HUVEC (Fig. 4B) . These results indicate that the cyclooxygenase inhibitor aspirin speci¢cally suppresses staphylococcal SMase-induced increase in PAI-1 release from HUVEC, but neither TNF-K-nor C 2 -ceramide-induced increase is a¡ected, suggesting a possible role of intracellular ceramide in the TNF-K signaling.
Discussion
In the present work, we indicate the possibility that the lysosomally generated ceramide-mediated signal transduction pathway(s) is involved in TNF-K-induced increase in PAI-1 release from HUVEC. This conclusion is based on the following observations. First, addition of TNF-K prominently increased the intracellular ceramide levels in HUVEC, but did not alter the membranous ceramide content (Fig. 1A) . Second, the increase in PAI-1 release was accompanied by a signi¢cant activation of the intracellular acidic SMase (Fig. 1B) . Third, C 2 -dihydroceramide, a derivative of C 2 -ceramide, suppressed the increase in PAI-1 release induced not only by the cell-permeable ceramide analog (Fig. 3A) , but also by TNF-K (Fig. 3B) . C 2 -dihydroceramide failed to suppress the increase in PAI-1 release induced by staphylococcal SMase (Fig. 3A) , while aspirin was found to selectively suppress the increase in PAI-1 release induced by the SMase, but not by TNF-K (Fig. 4A,B) .
However, the increase in the intracellular ceramide levels observed after TNF-K stimulation was signi¢-cant, but very small (26% increase). The kinetics of ceramide formation in response to TNF-K are very di¡erent in di¡erent studies. TNF-K appears to induce prolonged and persistent accumulation of ceramide that occurs over a period of several hours, but serum withdrawal from culture medium also affects the ceramide accumulation [19] . In this study, the exchange of EGM-MV for serum-free DMEM may have resulted in an increase in the ceramide levels of control cells.
When considering the role of ceramide in the signal transduction, the most important thing is that where, but not how much, the intracellular lipid mediator was generated. The increased ceramide is probably due to the hydrolysis of SM by lysosomal acidic SMase (TNF-K induced a 33% increase in activity). The lysosomally generated ceramide might induce a signal for the production of PAI-1. However, Slowik et al. [20] reported that the treatment of HUVEC with TNF-K did not alter the intracellular ceramide and SM levels, but activated NF-UB. This suggests that TNF-K does not activate the SMaseceramide signaling pathway in HUVEC. One of the reasons by which these contradicting results occurred may be due to the di¡erence in culture conditions. Although we cultivated HUVEC in MCDB 131 substituted with 5% serum and supplements, such as epidermal growth factor, hydrocortisone, and bovine brain extract prior to the experiments with serumfree DMEM, they used a medium 199 supplemented with 20% serum. Since there is a report that describes acute changes in intracellular ceramide levels caused by changes in culture conditions [21] , preactivation of HUVEC with di¡erent supplements could account for the di¡erent results. Additionally, we used a higher concentration of TNF-K (200 U/ml) in our experiments as compared to 100 U/ml used by Slowik et al. [20] . The di¡erence in dose of TNF-K does not account for the di¡erent results, since 100 U/ml of TNF-K induced PAI-1 to near the maximal level in our experiments (a 2.5-fold increase, data not shown).
A 3-h treatment of HUVEC with 10 WM C 2 -ceramide induced a 2.1-fold increase in PAI-1 release ( Fig. 2A) . However, TNF-K increased PAI-1 release by 2.8-fold in spite of a small increase in the intracellular ceramide levels (approx. 200 ng/5U10 5 cells). This discrepancy may be explained as follows. First, the added C 2 -ceramide does not seem to be perfectly incorporated into the cells. Second, since the alkyl chain length of C 2 -ceramide is extremely short, it may be unable to act as fully as the intracellular ceramides. Additionally, 10 WM C 2 -ceramide and TNF-K (200 U/ml) in combination did not a¡ect the sole e¡ect of TNF-K on PAI-1 production (data not shown), suggesting that both inducers utilize the same signal transduction pathway.
Endogenous dihydroceramide is rapidly converted to ceramide by the desaturase(s) present in the site of microsomes [22] . In our system, however, C 2 -dihydroceramide still had the suppressive e¡ect over 6 h (data not shown), suggesting that it was hardly converted to C 2 -ceramide. Michel et al. [23] have clearly demonstrated the in vitro conversion of dihydroceramide to ceramide, using rat liver microsomes. They have shown that the desaturase activity is in£uenced by the alkyl chain length of the sphingoid base (in the order C 18 s C 12 s C 8 ). This ¢nding allowed us to
